GSK 2798745

Drug Profile

GSK 2798745

Alternative Names: GSK-2798745

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Biomedical Advanced Research and Development Authority; GlaxoSmithKline
  • Class Cardiovascular therapies
  • Mechanism of Action TRPV4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cough; Heart failure
  • Phase I Unspecified
  • No development reported Pulmonary oedema

Most Recent Events

  • 25 Jun 2018 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO) (NCT03511105)
  • 27 Apr 2018 GlaxoSmithKline plans a phase I trial for Healthy volunteers in May 2018 , (NCT03511105)
  • 05 Apr 2018 Phase-II clinical trials in Cough in United Kingdom (PO) (NCT03372603)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top